Company Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.7811 ^USD	-1.13%		-2.63%	-12.14%

Apr. 05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT
Apr. 05	Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	MT

Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.

Number of employees: 210

Managers	Title	Age	Since
Sergio Quezada FOU	Founder	49	20-10-31
Karl Peggs FOU	Founder	57	20-10-31
Iraj Ali CEO	Chief Executive Officer	48	17-12-31
Robert Coutts DFI	Director of Finance/CFO	40	20-10-31
Edward Samuel CTO	Chief Tech/Sci/R&D Officer	-	22-01-31
Shree Patel COO	Chief Operating Officer	-	-
James Taylor PRN	Corporate Officer/Principal	-	22-06-30
Tariq Ahmed HRO	Human Resources Officer	-	20-02-29
Daniel Hood LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Carsten Boess BRD	Director/Board Member	57	20-03-31
Edwin Moses CHM	Chairman	69	-
Bernhard R. M. Ehmer BRD	Director/Board Member	69	22-05-03
Michael Giordano BRD	Director/Board Member	66	18-08-31
Julie O'Neill BRD	Director/Board Member	58	21-05-02
Iraj Ali CEO	Chief Executive Officer	48	17-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	41,082,948	38,437,984 ( 93.56 %)	0	93.56 %

Name	Equities	%	Valuation
Syncona Portfolio Ltd. 27.08 %	11,086,909	27.08 %	14 M $
Forbion Capital Partners Management Holding BV 5.838 %	2,390,050	5.838 %	3 M $
Baker Bros. Advisors LP 5.136 %	2,102,792	5.136 %	3 M $
Redmile Group LLC 3.928 %	1,608,089	3.928 %	2 M $
Artal Group SA 3.664 %	1,500,000	3.664 %	2 M $
Point72 Asset Management LP 3.453 %	1,413,809	3.453 %	2 M $
Invus Public Equities Advisors LLC 1.845 %	755,375	1.845 %	944 219 $
Renaissance Technologies LLC 1.219 %	498,995	1.219 %	623 744 $
Citadel Securities GP LLC 0.2649 %	108,454	0.2649 %	135 568 $
Vestal Point Capital LP 0.2640 %	108,083	0.2640 %	135 104 $

Name	Equities	%	Valuation
Baker Bros. Advisors LP -	1,208,775	-	2 M $

Name	Equities	%	Valuation
Forbion Capital Partners Management Holding BV 5.884 %	2,390,050	5.884 %	3 M $
Iraj Ali 2.357 %	957,559	2.357 %	1 M $
Invus Public Equities Advisors LLC 1.860 %	755,375	1.860 %	944 219 $
LSP Advisory BV 1.349 %	548,004	1.349 %	685 005 $
Karl Peggs 1.319 %	535,804	1.319 %	669 755 $
Sergio Quezada 0.9189 %	373,257	0.9189 %	466 571 $
Edwin Moses 0.5939 %	241,250	0.5939 %	301 563 $
Robert Coutts 0.4688 %	190,431	0.4688 %	238 039 $
Michael Giordano 0.1149 %	46,663	0.1149 %	58 329 $
BG Fund Management Luxembourg SA 0.0441 %	17,900	0.0441 %	22 375 $

Achilles Therapeutics Plc

245 Hammersmith Road

W6 8PW, London

+44 20 8154 4600

http://www.achillestx.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7811 USD

Average target price

4.125 USD

Spread / Average Target

+428.10%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACHILLES THERAPEUTICS PLC	-12.14%	32.09M
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+48.32%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research